Home › Trials › NCT06633380
Clinical trial Recruiting at 1 site Interventional Women only

Short post-meal activity and spread-out exercise for breast cancer survivors

Official title: Alternative Physical Activity Strategies for Breast and Prostate Cancer Survivors

Run by University of Toronto · NCT06633380 · Data updated 2026-11-12

We will test whether short bouts of activity after meals or spreading activity through the day better lower blood sugar than no activity or a standard 30‑minute workout in sedentary, postmenopausal breast cancer survivors on aromatase inhibitors and similar women without cancer.

More Breast Cancer trials

Quick facts

Study typeInterventional
SexWomen only
Enrollment24 (estimated)
SponsorUniversity of Toronto
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedOctober 22, 2024
Main results expectedApril 30, 2026
Study endsJuly 1, 2026
Registry record updatedDecember 2, 2025
Trial IDNCT06633380 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are postmenopausal biological females with BMI ≥25 kg/m² who are sedentary and eat three main meals daily, including those with stage I–III breast cancer who have used aromatase inhibitors for at least three months, as well as age- and BMI-matched postmenopausal women without a cancer history.

Probably not a fit

People who are already regularly active, who have uncontrolled cardiovascular disease, significant diabetes or renal disease without medical clearance, or who cannot obtain physician clearance are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares two alternative physical activity strategies (dispersed post-meal activity and brief “PA snacks”) with a no-activity condition and with standard 30-minute aerobic or resistance sessions. Participants are sedentary, postmenopausal women including breast cancer survivors on aromatase inhibitors and age- and BMI-matched controls without cancer. The primary outcomes are acute glycemic responses, including 24-hour glucose and postprandial glucose, measured across the different activity conditions. Secondary and exploratory aims look at acceptability and feasibility in free-living conditions and whether responses differ by cancer history and aromatase inhibitor use.

Why it matters

Potential benefit: If successful, these simple activity patterns could offer an easy way to improve blood sugar control and lower cardiometabolic risk for breast cancer survivors on hormone therapy.

How similar studies have gone: Prior research in general and cardiometabolic populations shows that post-meal walking and breaking up sitting can lower postprandial glucose, but these approaches are less well tested specifically in breast cancer survivors on aromatase inhibitors.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Postmenopausal biological females diagnosed with stage I, II, or III breast cancer and currently using aromatase inhibitors (AI) for at least 3 months prior to start of study participation
* All participants must meet the following criteria:

  * Body mass index equal to or greater than 25 kg/m\^2.
  * Self-report consuming three main meals daily.
  * Self-report as being sedentary (i.e., less than 30 minutes/week of moderate-to-vigorous aerobic physical activity and less than twice/week muscle strengthening of major muscle groups in the last three months.

Exclusion Criteria:

* If unable or unwilling to receive medical clearance by a physician after being screened for major signs or symptoms of cardiovascular diseases, diabetes, or renal disease and safety to initiate exercise.

  * Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease are taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1. They include pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, and unusual fatigue with usual activities.
  * Safety to initiate exercise will be screened using the Get Active Questionnaire, which is the Canadian Society of Exercise Physiology's endorsed evidence-based pre-screening tool.
* Using drugs for diabetes management (e.g., exogenous insulin, Ozempic, metformin, etc.) or actively losing weight (i.e., \>5 kg weight loss in past 3 months) from drugs or other reasons
* Report any injury or other reason for not feeling capable of completing a 30 minute continuous walk or muscle strengthening exercise
* Unable to access an Ontario Lifelabs location for an overnight fasted blood draw
* Do not have a smartphone compatible with the applications required to collect data.
* Cannot read and understand the consent form or communicate in English.

Where it's running

  • Remote Ontario-wide
    Toronto, Ontario, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Breast Cancer 2490Insulin Resistance 165Cardiometabolic Risk Factors 19University of Toronto 45
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.